JJJohann de Jong

Johann de Jong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Johann de Jong has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Image-based Disease-wide Association Study via Self-supervised Learning links Abdominal MRI Features to 158 Diseases

    by Seyed Mousavi, Jatin Arora, Richa Agarwal, Anja Fischer, Stefanie Mueller, Zhihao Ding, Johann de Jong, Ke Yuan

    Medical images contain rich phenotypic information that is often not fully captured by manual clinical assessment. Here, we present a systematic framework for extracting such information and conducting image-based disease-wide association studies (iDWAS) using self-supervised learning (SSL). We applied this framework to abdominal MRI data from the UK Biobank and evaluated associations between MRI-derived features and diseases. Features were learned using a VICReg-based SSL model and tested for disease associations using logistic regression models. We identified 158 diseases that were significantly associated with the MRI-derived features, including the ones which are not directly linked to abdominal anatomy. Focusing on metabolic dysfunction-associated steatohepatitis (MASH), we showed that the MRI-derived features captured disease-relevant information and separated MASH cases from controls better than established biomarkers such as PDFF and Iron-cT1. These findings highlight the ability of SSL to uncover clinically meaningful signals from routine imaging data. The proposed framework is broadly applicable to other imaging datasets and modalities, enabling more systematic approaches to incidental and early disease detection. The trained model and analysis pipeline are publicly available at https://github.com/srm2022/iDWAS.

  • Open Access

    Deep representation learning for clustering longitudinal survival data from electronic health records

    by Jiajun Qiu, Yao Hu, Li Li, Abdullah Mesut Erzurumluoglu, Ingrid Braenne, Charles Whitehurst, Jochen Schmitz, Jatin Arora, Boris Alexander Bartholdy, Shrey Gandhi, et al.

    Precision medicine requires accurate identification of clinically relevant patient subgroups. Electronic health records provide major opportunities for leveraging machine learning approaches to uncover novel patient subgroups. However, many existing approaches fail to adequately capture complex interactions between diagnosis trajectories and disease-relevant risk events, leading to subgroups that can still display great heterogeneity in event risk and underlying molecular mechanisms. To address this challenge, we implemented VaDeSC-EHR, a transformer-based variational autoencoder for clustering longitudinal survival data as extracted from electronic health records. We show that VaDeSC-EHR outperforms baseline methods on both synthetic and real-world benchmark datasets with known ground-truth cluster labels. In an application to Crohn’s disease, VaDeSC-EHR successfully identifies four distinct subgroups with divergent diagnosis trajectories and risk profiles, revealing clinically and genetically relevant factors in Crohn’s disease. Our results show that VaDeSC-EHR can be a powerful tool for discovering novel patient subgroups in the development of precision medicine approaches.


  • Open Access

    Towards realizing the vision of precision medicine: AI based prediction of clinical drug response

    by Johann de Jong, Ioana Cutcutache, Matthew Page, Sami Elmoufti, Cynthia Dilley, Holger Fröhlich, Martin Armstrong

    Accurate and individualized prediction of response to therapies is central to precision medicine. However, because of the generally complex and multifaceted nature of clinical drug response, realizing this vision is highly challenging, requiring integrating different data types from the same individual into one prediction model. We used the anti-epileptic drug brivaracetam as a case study and combine a hybrid data/knowledge-driven feature extraction with machine learning to systematically integrate clinical and genetic data from a clinical discovery dataset (n = 235 patients). We constructed a model that successfully predicts clinical drug response [area under the curve (AUC) = 0.76] and show that even with limited sample size, integrating high-dimensional genetics data with clinical data can inform drug response prediction. After further validation on data collected from an independently conducted clinical study (AUC = 0.75), we extensively explore our model to gain insights into the determinants of drug response, and identify various clinical and genetic characteristics predisposing to poor response. Finally, we assess the potential impact of our model on clinical trial design and demonstrate that, by enriching for probable responders, significant reductions in clinical study sizes may be achieved. To our knowledge, our model represents the first retrospectively validated machine learning model linking drug mechanism of action and the genetic, clinical and demographic background in epilepsy patients to clinical drug response. Hence, it provides a blueprint for how machine learning-based multimodal data integration can act as a driver in achieving the goals of precision medicine in fields such as neurology.


  • Open Access

    Deep learning for clustering of multivariate clinical patient trajectories with missing values

    by Johann de Jong, Mohammad Asif Emon, Ping Wu, Reagon Karki, Meemansa Sood, Patrice Godard, Ashar Ahmad, Henri Vrooman, Martin Hofmann-Apitius, Holger Fröhlich

    Background: Precision medicine requires a stratification of patients by disease presentation that is sufficiently informative to allow for selecting treatments on a per-patient basis. For many diseases, such as neurological disorders, this stratification problem translates into a complex problem of clustering multivariate and relatively short time series because (i) these diseases are multifactorial and not well described by single clinical outcome variables and (ii) disease progression needs to be monitored over time. Additionally, clinical data often additionally are hindered by the presence of many missing values, further complicating any clustering attempts. Findings: The problem of clustering multivariate short time series with many missing values is generally not well addressed in the literature. In this work, we propose a deep learning–based method to address this issue, variational deep embedding with recurrence (VaDER). VaDER relies on a Gaussian mixture variational autoencoder framework, which is further extended to (i) model multivariate time series and (ii) directly deal with missing values. We validated VaDER by accurately recovering clusters from simulated and benchmark data with known ground truth clustering, while varying the degree of missingness. We then used VaDER to successfully stratify patients with Alzheimer disease and patients with Parkinson disease into subgroups characterized by clinically divergent disease progression profiles. Additional analyses demonstrated that these clinical differences reflected known underlying aspects of Alzheimer disease and Parkinson disease. Conclusions: We believe our results show that VaDER can be of great value for future efforts in patient stratification, and multivariate time-series clustering in general.


  • Open Access

    Multiplexed Cas9 targeting reveals genomic location effects and gRNA-based staggered breaks influencing mutation efficiency

    by Santiago Gisler, Joana P. Gonçalves, Waseem Akhtar, Johann de Jong, Alexey V. Pindyurin, Lodewyk F. A. Wessels, Maarten van Lohuizen

    Understanding the impact of guide RNA (gRNA) and genomic locus on CRISPR-Cas9 activity is crucial to design effective gene editing assays. However, it is challenging to profile Cas9 activity in the endogenous cellular environment. Here we leverage our TRIP technology to integrate ~ 1k barcoded reporter genes in the genomes of mouse embryonic stem cells. We target the integrated reporters (IRs) using RNA-guided Cas9 and characterize induced mutations by sequencing. We report that gRNA-sequence and IR locus explain most variation in mutation efficiency. Predominant insertions of a gRNA-specific nucleotide are consistent with template-dependent repair of staggered DNA ends with 1-bp 5′ overhangs. We confirm that such staggered ends are induced by Cas9 in mouse pre-B cells. To explain observed insertions, we propose a model generating primarily blunt and occasionally staggered DNA ends. Mutation patterns indicate that gRNA-sequence controls the fraction of staggered ends, which could be used to optimize Cas9-based insertion efficiency.


  • Open Access

    The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells

    by Martine van Keimpema, Leonie J. Grüneberg, Esther J.M. Schilder-Tol, Monique E.C.M. Oud, Esther A. Beuling, Paul J. Hensbergen, Johann de Jong, Steven T. Pals, Marcel Spaargaren

    The forkhead transcription factor FOXP1 is generally regarded as an oncogene in activated B cell-like diffuse large B-cell lymphoma. Previous studies have suggested that a small isoform of FOXP1 (FOXP1-iso), rather than full-length FOXP1 (FOXP1-FL), may possess this oncogenic activity. Corroborating those studies, we here show that activated B cell-like diffuse large B-cell lymphoma cell-lines and primary activated B cell-like diffuse large B-cell lymphoma cells predominantly express FOXP1-iso and that the 5-end of the Foxp1 gene is a common insertion site in murine lymphomas in leukaemia virus- and transposon-mediated insertional mutagenesis screens. By combined mass-spectrometry, (q)RT-PCR/sequencing, and siRNA-mediated gene-silencing, we determined that FOXP1-iso predominantly expressed in activated B cell-like diffuse large B-cell lymphoma lacks the N-terminal 100 amino acids of FOXP1-FL. Aberrant overexpression of FOXP1-iso (ΔN100) in primary human B cells revealed its oncogenic capacity: it repressed apoptosis and plasma cell differentiation. However, no difference in potency was found between FOXP1-iso and FOXP1-FL. Furthermore, overexpression of FOXP1-FL or FOXP1-iso in primary B cells and diffuse large B-cell lymphoma cell-lines resulted in similar gene regulation. Taken together, our data indicate that FOXP1-iso and FOXP1-FL have comparable oncogenic and transcriptional activity, suggesting that aberrant (over)expression of FOXP1, irrespective of the specific isoform, contributes to lymphomagenesis. These novel insights further enhance the value of FOXP1 for the diagnostics, prognostics, and treatment of diffuse large B-cell lymphoma patients.


  • Open Access

    Analysis of a spatial gene expression database for sea anemone Nematostella vectensis during early development

    by Daniel Botman, Fredrik Jansson, Eric Röttinger, Mark Q. Martindale, Johann de Jong, Jaap A. Kaandorp

    The spatial distribution of many genes has been visualized during the embryonic development in the starlet sea anemone Nematostella vectensis in the last decade. In situ hybridization images are available in the Kahi Kai gene expression database, and a method has been developed to quantify spatial gene expression patterns of N. vectensis. In this paper, gene expression quantification is performed on a wide range of gene expression patterns from this database and descriptions of observed expression domains are stored in a separate database for further analysis. Spatial gene expression from suitable in situ hybridization images has been quantified with the GenExp program. A correlation analysis has been performed on the resulting numerical gene expression profiles for each stage. Based on the correlated clusters of spatial gene expression and detailed descriptions of gene expression domains, various mechanisms for developmental gene expression are proposed. In the blastula and gastrula stages of development in N. vectensis, its continuous sheet of cells is partitioned into correlating gene expression domains. During progressing development, these regions likely correspond to different fates. A statistical analysis shows that genes generally remain expressed during the planula stages in those major regions that they occupy at the end of gastrulation. Observed shifts in gene expression domain boundaries suggest that elongation in the planula stage mainly occurs in the vegetal ring under the influence of the gene Rx. The secondary body axis in N. vectensis is proposed to be determined at the mid blastula transition. Early gene expression domains in N. vectensis appear to maintain a positional order along the primary body axis. Early determination in N. vectensis occurs in two stages: expression in broad circles and rings in the blastula is consolidated during gastrulation, and more complex expression patterns appear in the planula within these broad regions. Quantification and comparison of gene expression patterns across a database can generate hypotheses about collective cell movements before these movements are measured directly.


  • TRIP through the chromatin: A high throughput exploration of enhancer regulatory landscapes

    by Alexey V. Pindyurin, Johann de Jong, Waseem Akhtar


  • Chemical profiling of the genome with anti-cancer drugs defines target specificities

    by Baoxu Pang, Johann de Jong, Xiaohang Qiao, Lodewyk F A Wessels, Jacques Neefjes

    Many anticancer drugs induce DNA breaks to eliminate tumor cells. The anthracycline topoisomerase II inhibitors additionally cause histone eviction. Here, we performed genome-wide high-resolution mapping of chemotherapeutic effects of various topoisomerase I and II (TopoI and II) inhibitors and integrated this mapping with established maps of genomic or epigenomic features to show their activities in different genomic regions. The TopoI inhibitor topotecan and the TopoII inhibitor etoposide are similar in inducing DNA damage at transcriptionally active genomic regions. The anthracycline daunorubicin induces DNA breaks and evicts histones from active chromatin, thus quenching local DNA damage responses. Another anthracycline, aclarubicin, has a different genomic specificity and evicts histones from H3K27me3-marked heterochromatin, with consequences for diffuse large B-cell lymphoma cells with elevated levels of H3K27me3. Modifying anthracycline structures may yield compounds with selectivity for different genomic regions and activity for different tumor types.


  • Erratum: Corrigendum: Using TRIP for genome-wide position effect analysis in cultured cells

    by Waseem Akhtar, Alexey V Pindyurin, Johann de Jong, Ludo Pagie, Jelle Ten Hoeve, Anton Berns, Lodewyk F A Wessels, Bas van Steensel, Maarten van Lohuizen